Key clinical point: Pembrolizumab increased 5-year overall survival for patients with advanced non–small cell lung cancer.
Major finding: The 5-year overall survival rate was 23.2% in treatment-naive patients and 15.5% in previously treated patients who received pembrolizumab in this study.
Study details: Phase 1b trial including 550 patients with advanced NSCLC.
Disclosures: The lead author disclosed relationships with AstraZeneca, Bristol-Myers Squibb, Dracen, Dynavax, Genentech, Iovance Biotherapeutics, Lilly, Merck, Mirati Therapeutics, Neon Therapeutics, and Novartis. The trial was sponsored by Merck Sharp & Dohme Corp.